{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:50:15Z","timestamp":1776714615248,"version":"3.51.2"},"reference-count":7,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2000]]},"abstract":"We studied the effects of meloxicam on prostanoid levels, both in the inflammatory site in rat carrageenin-induced pleurisy and in the rat stomach injected with 1\u00a0mol\/l NaCl solution, to clarify the relationship between its low gastric toxicity and its relative cyclooxygenase (COX) 2 selectivity. NS-398 (3 mg\/kg), a highly selective COX-2 inhibitor, and meloxicam (3 mg\/kg) exhibited anti-inflammatory effects in the pleurisy model. Prostaglandin (PG) E<sub>2<\/sub> thromboxane (TX) B<sub>2<\/sub> and 6-keto-PGF<sub>1\u03b1<\/sub> were detectable in the inflammatory site. Anti-inflammatory doses of NS-398 and meloxicam each suppressed the intrapleural PGE<sub>2<\/sub> level at 5\u00a0h as potently as piroxicam (3\u00a0mg\/kg) as aspirin (100 mg\/kg), both of which are nonselective COX inhibitors. NS-398 was much less potent than the other three in suppressing the levels of TXB<sub>2<\/sub> and 6-keto-PGF<sub>1\u03b1<\/sub>. These results suggest that PGE<sub>2<\/sub> may be produced mainly via COX-2 in this model and that meloxicam may inhibit COX-2 in the inflammatory site. Piroxicam completely inhibited the increase in gastric PGE<sub>2<\/sub> induced by administering 1 mol\/l NaCl solution into the rat stomach. Nimesulide (3 mg\/kg), another selective COX-2 inhibitor, however, never affected this increase, suggesting that the gastric PGE<sub>2<\/sub> may be produced via COX-1. The anti-inflammatory dose of meloxicam caused statistically nonsignificant suppression of the PGE<sub>2<\/sub> level, by approximately 50%. These results suggest that the potent anti-inflammatory effect of meloxicam, accompanied with low gastric toxicity, may be related to its relative selectivity for COX-2 over COX-1.<\/jats:p>","DOI":"10.1159\/000028408","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T13:07:10Z","timestamp":1050412030000},"page":"244-250","source":"Crossref","is-referenced-by-count":13,"title":["Meloxicam Inhibits Prostaglandin E<sub>2<\/sub> Generation via Cyclooxygenase 2 in the Inflammatory Site but Not That via Cyclooxygenase 1 in the Stomach"],"prefix":"10.1159","volume":"61","author":[{"given":"Keiko","family":"Ogino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiteru","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2000,11,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.52.33157"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(94)90074-4"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(86)90008-0"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(82)90131-9"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)00212-X"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7220"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/41780"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/28408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/28408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:16:05Z","timestamp":1745468165000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000028408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":7,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2000,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000028408","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"value":"0031-7012","type":"print"},{"value":"1423-0313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000]]}}}